Serum iron, infection and inflammation; effects on coronary risk

Scandinavian Cardiovascular Journal

Volumn 38, Issue 6, 2004, Pages 345-348

  Kervinen, Helena ^a   Tenkanen, Leena ^a   Palosuo, Timo ^b   Roivainen, Merja ^b   Manninen, Vesa ^a   Mänttäri, Matti ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c JORVI HOSPITAL   (Finland)

Author keywords

Coronary heart disease; Infection; Inflammation; Iron

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; GEMFIBROZIL; IRON; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; FERRITIN BLOOD LEVEL; HEART DEATH; HEART INFARCTION; HERPES SIMPLEX VIRUS 1; HUMAN; INFECTION; IRON BLOOD LEVEL; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY DISEASE; HERPESVIRUS 1, HUMAN; HUMANS; INFECTION; INFLAMMATION; IRON; LEUKOCYTE COUNT; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 12344252576     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430410011003     Document Type: Article

References (28)

1. Fuhrman B, Oiknine J, Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 1994; 111: 65-78.
2. Morgan J, Leake DS. Oxidation of low-density lipoprotein by iron and copper at acidic pH. J Lipid Res 1995; 36: 2504-2512.
3. Lynch CM, Frei B. Mechanism of copper- and iron-dependent oxidative modification of human low density lipoprotein. J Lipid Res 1993; 34: 1745-1753.
4. Steinberg D, Pathasarathy S, Carew TE, et al. Beyond cholesterol: Modifications of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915-924.
5. Steinberg D. Antioxidants and atherosclerosis: A current assessment. Circulation 1991; 84: 1420-1425.
6. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117: 1177-1188.
7. Reunanen A, Takkunen H, Knekt O, et al. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med 1995; 238: 223-230.
8. Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: Negative findings from the NHANES I study epidemiologic follow-up study. Am J Epidemiol 1994; 139: 704-712.
9. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994; 5: 135-137.
10. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803-811.
11. Mänttäri M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994; 15: 1599-1603.
12. Toivanen P, Manninen V, Tenkanen L, et al. Low serum iron increases the risk of coronary events. Eur Heart J 1998; 19: Abstr Suppl 554.
13. Mänttäri M, Kervinen H, Tenkanen L, et al. Synergistic effects of low serum iron and inflammation on coronary risk. Circulation 2002; 106: II-729.
14. Corti M-C, Guralnik JM, Salive ME, et al. Serum iron level, coronary artery disease and all-cause mortality in older men and women. Am J Cardiol 1997; 79: 120-127.
15. Stampfer MJ, Grodstein F, Rosenberg I, et al. A prospective study of plasma ferritin and risk myocardial infarction in US physicians. Circulation 1993; 87: 688.
16. Aronow WS. Serum ferritin is not a risk factor for coronary artery disease in men and women ≥62 years. Am J Cardiol 1993; 72: 347-348.
17. Magnusson MK, Sigfusson N, Sigvaldason H, et al. Low iron binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-108.
18. Sempos CT, Locker AC, Gillum RF, et al. Body iron stores and the risk of coronary disease. N Engl J Med 1994; 330: 1119-1124.
19. Danesh J, Appleby P. Coronary heart disease and iron status. Circulation 1999; 99: 852-854.
20. Jonasson L, Holm J, Skalli O, et al. Regional accumulation of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Atherosclerosis 1986; 6: 131-138.
21. Moreno PR, Fuster V, Palacios IF, et al. Increased macrophage plaque infiltration in patients with acute coronary syndromes. Circulation 1994; 90: 775-778.
22. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the pre-dilection site of atheromatous rupture. Circulation 1994; 90: 1669-1678.
23. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
24. Konijn AM, Hershko C. Ferritin synthesis in inflammation. Pathogenesis of impaired iron release. Br J Haematol 1977; 37: 7-16.
25. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
26. Heinonen OP, Huttunen JK, Manninen V, et al. The Helsinki Heart Study: Coronary heart disease incidence during an extended follow-up. J Intern Med 1994; 235: 41-49.
27. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation and the risk of coronary disease. Circulation 2000; 101: 252-257.
28. Mattioli AV, Bonetti L, Zennaro M, et al. Prognostic value of iron, nutritional status indexes and acute phase protein in acute coronary syndromes. Ital Heart J 2002; 3(3): 194-198.